表紙
市場調查報告書

細胞治療及基因治療市場

Cell Therapy and Gene Therapy Markets

出版商 Kalorama Information 商品編碼 939475
出版日期 內容資訊 英文 247 Pages
商品交期: 最快1-2個工作天內
價格
細胞治療及基因治療市場 Cell Therapy and Gene Therapy Markets
出版日期: 2020年04月27日內容資訊: 英文 247 Pages
簡介

細胞治療及基因治療產品,不僅造成癌症和遺傳病的治療變革,自體免疫疾病,心血管疾病,肌肉骨骼系統疾病,皮膚科疾病等,在很多其他醫療領域也擴大。

本報告提供全球細胞治療及基因治療市場相關調查,各症狀/疾病的市場分析與預測,主要產品,研究開發趨勢,市場明細,地區市場,競爭情形,及主要企業的簡介等系統性資訊。

第1章 摘要整理

  • 概要
  • 範圍與方法調查手法
  • 市場概要與未來性
  • 冠狀病毒的細胞及基因治療開發平台

第2章 簡介:細胞治療、基因治療

  • 簡介
  • 細胞及基因治療:特徵
  • 人員編制
  • CAR-T的製造流程
  • 製造流程的進步與阻礙
  • 成本
  • 償付
  • 物流
  • 合併和收購
  • 法規的發展
  • 開發與開發平台概要
  • 開發的進展
  • 開發:各症狀/疾病
  • 階段III開發
  • 終端用戶

第3章 皮膚科的細胞治療、基因治療市場

  • 概要
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 市場明細
  • 皮膚科的細胞治療、基因治療市場:各症狀
  • 地區市場概要
  • 競爭企業概要

第4章 心血管及血液疾病的細胞治療、基因治療市場

  • 概要
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 地區市場概要
  • 競爭企業概要

第5章 腫瘤學的細胞治療、基因治療市場

  • 概要
  • 癌症增生的原因
  • 全球癌症負擔
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 地區市場概要
  • 競爭企業概要

第6章 眼科疾病的細胞治療、基因治療市場

  • 概要
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 市場明細
  • 地區市場概要
  • 競爭企業概要

第7章 肌肉骨骼症狀、疾病的細胞治療、基因治療市場

  • 概要
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 市場明細
  • 地區市場概要
  • 競爭企業概要

第8章 其他疾病的細胞治療、基因治療市場

  • 概要
  • 市場展望
  • 主要產品
  • 研究開發趨勢
  • 市場明細
  • 地區市場概要
  • 競爭企業概要

第9章 細微細胞治療、基因治療市場檢討

  • 市場影響要素
  • 全球市場概要
  • 細胞治療 vs. 基因治療市場
  • 地區市場概要
  • 美國
  • 歐洲/歐洲聯盟
  • 其他的國家
  • 競爭企業排行榜

第10章 市場參與企業

  • 主要企業
  • ADVANTAGENE,INC
  • ADVAXIS,INC
  • ALLOSOURCE
  • ALNYLAM PHARMACEUTICALS
  • AMGEN
  • ANGES INC
  • ANTEROGEN CO LTD
  • ATARA BIOTHERAPEUTICS
  • ATHERSYS,INC
  • AVEXIS,INC
  • BIOCARDIA
  • BIOGEN, INC.
  • IOMARIN PHARMACEUTICALS
  • BRAINSTORM CELL THERAPEUTICS
  • CALADRIUS BIOSCIENCES
  • CELYAD
  • COOK MYOSITE, INC
  • CYTORI THERAPEUTICS,INC
  • DENDREON PHARMACEUTICALS LLC 、另外
目錄
Product Code: 20-030

This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others. ‘Cell Therapy and Gene Therapy Markets ’ presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

  • Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
  • Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:

Dermatology, including:

  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Cardiovascular and Blood Disorders, including:

  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)

Oncology, including:

  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Ophthalmic Conditions, including:

  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)

Musculoskeletal Conditions and Disorders, including:

  • Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

Other Conditions, including:

  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

‘Cell Therapy and Gene Therapy Markets’ also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.

The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:

  • Vitro Biopharma
  • Celularity and Sorrento Therapeutics
  • CanSino Biologics
  • Mesoblast
  • Acturus Therapeutics
  • Entos Pharmaceuticals
  • Zydus Cadila
  • AlloVir and Baylor College of Medicine
  • Athersys
  • Exothera
  • Sirnaomics
  • Mesoblast

The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:

  • Advantagene
  • Advaxis
  • AlloSource
  • Alnylam Pharmaceuticals
  • Amgen
  • AnGes USA
  • Anterogen
  • Atara Therapeutics
  • Athersys
  • AveXis
  • BioCardia
  • BioMarin Pharmaceuticals
  • Bluebird bio
  • BrainStorm Cell Therapeutics
  • Caladrius Bioscience
  • Celyad
  • Cook MyoSite
  • Cytori Therapeutics
  • Dendreon
  • Ferring Pharmaceuticals
  • Fibrocell
  • Gamida Cell
  • GenSight Biologics
  • Genzyme
  • Gilead Sciences
  • Gradalis
  • Inovio Pharmaceuticals
  • Kiadis Pharma
  • Medeor Therapeutics
  • Medipost
  • Merck
  • Mesoblast
  • MolMed
  • Neurotech USA
  • Nightstar Therapeutics
  • Northwest Biotherapeutics
  • Novartis
  • NuVasive
  • Orchard Therapeutics
  • Organogenesis
  • Orthofix
  • Osiris Therapeutics (part of Smith & Nephew)
  • Pharmicell
  • Pluristem Therapeutics
  • Quark Pharmaceuticals
  • Renova Therapeutics
  • Sanofi Pasteur
  • SOTIO
  • Spark Therapeutics
  • Tessa Therapeutics
  • Tocagen
  • uniQure
  • VBL Therapeutics
  • ViroMed

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and expected market for 2020 based on first quarter company reports and is expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers' revenues.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • MARKET OVERVIEW AND POTENTIAL
    • Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2019-2030 (Dermatological, Cardiovascular-Blood, Oncology, Ophthalmic, Musculoskeletal, Other Conditions)
  • CORONAVIRUS CELL AND GENE THERAPY PIPELINE

CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY

  • INTRODUCTION
    • Cell Therapy
      • Table 2-1: Adult vs. Embryonic Stem Cells
    • Gene Therapy
      • Table 2-2: Somatic vs. Germ Line Gene Therapy
    • Viral Vector System and New Developments
      • Table 2-3: Examples of Viruses in Gene Therapy
      • Figure 2-1: Gene Therapy Vector Type Distribution, Commercialized (current and former) Products (%) (Retrovirus and Gamma-Retrovirus, Lentiviral, Non-viral, Herpes Simplex Virus, Adeno and Adeno-associated Virus)
    • Non-viral Systems for Transporting Genes
    • Gene Editing
  • CELL AND GENE THERAPY: CHARACTERISTICS
    • Table 2-4: Cell Therapy vs. Gene Therapy
    • Table 2-5: Autologous vs. Allogeneic Cell and Gene Therapies, Commercialized Products
    • Figure 2-2: Cell and Gene Therapy, Autologous and Allogeneic Distribution for Commercialized Products (%)
    • Figure 2-3: Cell and Gene Therapy (combined autologous and allogeneic), Route of Administration Distribution for Commercialized Products (%) (Topical, Implant, Intravenous, Injection)
  • STAFFING
  • MANUFACTURING PROCESS FOR CAR-T
    • Leukapheresis
    • Activation
    • Transduction
    • Expansion
  • ADVANCEMENTS AND BARRIERS IN MANUFACTURING PROCESSES
    • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
    • Figure 2-4: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
  • COST
  • REIMBURSEMENT
  • LOGISTICS
  • MERGERS AND ACQUISITIONS
    • Table 2-7: Select Company Mergers and Acquisitions in the Cell and Gene Therapy Market
  • REGULATORY DEVELOPMENTS
    • Fast Track
    • Orphan Drug
    • Breakthrough Therapy
    • Accelerated Approval
    • Priority Review
      • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
    • Individualized Gene Therapy Approval Process
  • DEVELOPMENT AND PIPELINE OVERVIEW
  • DEVELOPMENT PROGRESS
    • Figure 2-5: Global Cell and Gene Therapy Development Progress (phase I through phase III)
    • Figure 2-6: Global Cell and Gene Therapy Development Progress by Phase (%)
  • DEVELOPMENT BY CONDITION/DISORDER
    • Figure 2-7: Global Development of Cell and Gene Therapies by Target (%) (Oncology; Genetic disorders; Hematology; Immunology; Endocrine, metabolic; Cardiovascular; Musculoskeletal disorders; Infectious disease; Ophthalmology; Gastroenterology; Respiratory; Dermatology; Neurology; Other disorders)
  • PHASE III DEVELOPMENT
    • Table 2-9: Phase III Development - Cell and Gene Therapies, Select Projects
    • Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)
  • END USER
    • Hospitals
    • Research Institutes
    • Wound Care Centers
    • Cancer Centers

CHAPTER 3: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY

  • OVERVIEW
    • Table 3-1: Wound Prevalence by Type
  • MARKET OUTLOOK
    • Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • Apligraf
    • CureSkin
    • Dermagraft
    • Epicel
    • Gintuit
    • Grafix
    • Holoderm
    • Kaloderm
    • KeraHeal/KeraHeal-Allo
    • LaViv
    • Orcel
    • Quencell
    • RECELL
    • Rosmir
    • Stravix
    • TransCyte
      • Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
      • Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2019
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
    • Table 3-4: Dermatology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
  • MARKET BREAKDOWN OF CELL AND GENE THERAPIES
    • Table 3-5: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
    • Figure 3-3: Dermatology Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions) (Stem cells, Skin cells)
    • Figure 3-4: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by Indication
    • Table 3-6: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
    • Figure 3-5: Dermatology Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions) (Wound healing/treatment, Others [wrinkles, scar treatment])
  • REGIONAL MARKET SUMMARY
    • Figure 3-6: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Canada, Australia/New Zealand, Japan, China, Other countries)
    • Table 3-7: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
    • Figure: 3-7: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Canada, China, Singapore, etc.])
  • COMPETITOR SUMMARY
    • Table 3-8: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

CHAPTER 4: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS

  • OVERVIEW
    • Cardiovascular Disease
    • Selected Blood Disorders
  • MARKET OUTLOOK
    • Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • Collategene
    • Hearticellgram
    • HeartSheet
    • Neovasculgen
    • Stempeucel
    • Zynteglo
    • Cord Blood Products
      • Table 4-1: Cell and Gene Therapy in Cardiovascular and Blood Disorders
      • Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2019
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase (%), March 2020 Data
    • Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
  • Phase III Development
    • Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through March 2020
  • Orphan Drug, Fast Track, Breakthrough Designations
    • Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through March 2020
  • MARKET BREAKDOWN OF CELL AND GENE THERAPIES
    • Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
    • Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions) (Stem cells, Other cell therapy, Gene therapy, Stromal cells)
    • Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Gene therapy, Stem cells, Other cell therapy, Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
    • Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
    • Figure 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, 2017 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
    • Figure 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication (wound healing/treatment vs. other indications), Estimated 2020 (%) (Blood disorders, Cardiac disorders, Vascular disorders, Hypercholesterolemia)
  • REGIONAL MARKET SUMMARY
    • Figure 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, India, Japan, Other countries)
    • Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Japan, Other countries)
    • Figure 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • COMPETITOR SUMMARY

CHAPTER 5: CELL AND GENE THERAPY MARKETS IN ONCOLOGY

  • OVERVIEW
    • Biochemistry of Cancer Cells
  • CAUSES OF CANCER GROWTH
    • Environmental Factors, DNA, RNA
      • Table 5-1: Virus Association with Human Cancer
    • Cellular Oncogenes
    • Tumor Suppressor Genes
    • CAR-T Therapies
  • GLOBAL CANCER BURDEN
    • Figure 5-1: Global Cancer Incidence Trends, 2010-2040
    • Figure 5-2: Incidence of Cancer by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder)
    • Figure 5-3: Distribution of Cancer Incidence by Type, 2018 (Lung, Breast, Colorectum, Prostate, Stomach, Liver, Oesophagus, Cervix uteri, Thyroid, Bladder, Others)
  • MARKET OUTLOOK
    • Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • APCeden
    • CreaVax-RCC
    • Gendicine
    • Imlygic
    • Immuncell-LC
    • Kymriah
    • Provenge
    • Yescarta
    • Zalmoxis
      • Table 5-2: Cell and Gene Therapy in Oncology
      • Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2019
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 5-3: Oncology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
    • Table 5-4: Oncology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified Cell)
    • Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, March 2020 Data (Phase I through Phase III) (Anal, Bladder, Brain, Breast, Cancer [unspecified], Cervical, Colorectal, Head & Neck, Hematologic [leukemia and general], Liver, Lung, Lymphoma, Melanoma, Multiple Myeloma, Other, Ovarian, Pancreatic, Prostate, Renal, Solid Tumors)
    • Phase III Development
      • Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through March 2020
    • Orphan Drug, Fast Track, Breakthrough Designations
      • Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
  • MARKET BREAKDOWN OF CELL AND GENE THERAPIES
    • Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
    • Figure 5-7: Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
    • Figure 5-8: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
    • Oncology Cell and Gene Therapy Market by Cancer Type
      • Table 5-8: Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
      • Figure 5-9: Oncology Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions) (Blood cancers [lymphoma, leukemia], Prostate cancer, Melanoma, Other cancer)
      • Figure 5-10: Oncology Cell and Gene Therapy Market by General Indication (Blood cancers, Prostate cancer, Melanoma, Other cancers), Estimated 2020 (%)
  • REGIONAL MARKET SUMMARY
    • Figure 5-11: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2019 (United States, Europe/European Union, S. Korea, Other countries)
    • Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 030 ($ millions) (United States, Europe/European Union, Other countries)
    • Figure: 5-12: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
  • COMPETITOR SUMMARY
    • Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

CHAPTER 6: CELL AND GENE THERAPY MARKETS IN OPHTHALMIC CONDITIONS

  • OVERVIEW
  • MARKET OUTLOOK
    • Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • Holoclar
    • Luxturna
      • Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase (%), March 2020 Data
    • Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)
    • Phase III Development
      • Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through March 2020
    • Orphan Drug, Fast Track, Breakthrough Designations
      • Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020
  • MARKET BREAKDOWN OF CELL AND GENE THERAPIES
    • Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
    • Figure 6-2: Ophthalmology Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
    • Figure 6-3: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Stem cells, Gene therapy, Other cell therapy)
  • REGIONAL MARKET SUMMARY
    • Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, Other countries)
    • Figure: 6-4: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
  • COMPETITOR SUMMARY

CHAPTER 7: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS

  • OVERVIEW
  • MARKET OUTLOOK
    • Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • AlloStem
    • BIO4
    • Carticel
    • Cartiform
    • CartiLife
    • Cartistem
    • ChondroCelect
    • Chondron
    • JACC
    • MACI
    • Ortho-ACI and Ortho-ATI
    • Ossron
    • Osteocel and Osteoplus
    • Spherox
    • Trinity Elite and Trinity Evolution
      • Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
      • Figure 7-2: Musculoskeletal Cell Therapy Approvals by Year or Year Range, through 2019
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase (%), March 2020 Data
    • Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method (%), March 2020 Data (Cell, Gene, Gene-modified cell)
  • MARKET BREAKDOWN OF CELL THERAPIES
    • Table 7-4: Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
    • Figure 7-3: Musculoskeletal Cell Therapy Market, 2017 - 2030 ($ millions)
    • Musculoskeletal Cell Therapy Market by Indication
      • Table 7-5: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
      • Figure 7-4: Musculoskeletal Cell and Gene Therapy Market by General Indication, 2017 - 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
      • Figure 7-5: Musculoskeletal Cell Therapy Market by General Indication (Cartilage treatment, Bone treatment and Other indications), Estimated 2020 (%) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • REGIONAL MARKET SUMMARY
    • Figure 7-6: Musculoskeletal Cell Therapy Approvals by Country/Region (%), through 2019 (United States, Europe/European Union, Other countries)
    • Table 7-6: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
    • Figure: 7-7: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries [Australia, Japan, Canada, India])
  • COMPETITOR SUMMARY
    • Table 7-7: Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)

CHAPTER 8: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS

  • OVERVIEW
  • MARKET OUTLOOK
    • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2019-2030 ($ millions)
  • PRINCIPAL PRODUCTS
    • Alofisel
    • Cupistem
    • Givlaari
    • Glybera
    • NeuroNata-R
    • Onpattro
    • Stemirac
    • Strimvelis
    • Temcell/Prochymal
    • Zolgensma
      • Table 8-1: Cell and Gene Therapy in Other Diseases and Disorders
  • TRENDS IN RESEARCH AND DEVELOPMENT
    • Table 8-2: Other Conditions and Disorders: Cell and Gene Therapies in Development by Segment and Phase (%), March 2020 Data (ALS, Alzheimer's disease, Autoimmune diseases, Diabetes, Fabry's disease, HIV, Immune/transplant, Infectious diseases (excluding HIV), Liver disease, Multiple sclerosis, Muscular dystrophy, Other conditions (not categorized), Other genetic (not listed), Other neurological (not listed), Parkinson's disease, PKU, Pompe disease, Renal disease, Respiratory diseases, Spinal cord injury, Traumatic brain injury, Urological disorders)
  • MARKET BREAKDOWN OF CELL AND GENE THERAPIES
    • Table 8-3: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
    • Figure 8-2: Other Conditions Cell and Gene Therapy Markets by Product Type, 2017 - 2030 ($ millions) (therapy, Gene therapy, Gene-modified cell therapy)
    • Figure 8-3: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2020 (%) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • REGIONAL MARKET SUMMARY
    • Table 8-4: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
    • Figure 8-4: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Other countries)
  • COMPETITOR SUMMARY

CHAPTER 9: CELL AND GENE THERAPY MARKET REVIEW

  • MARKET INFLUENCES
    • Global Demographics
      • Table 9-1: Global Population, through 2050 (population in millions)
      • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
    • Cost Containment
      • Table 9-2: Cost Comparisons for Commercialized Cell and Gene Therapies
  • GLOBAL MARKET SUMMARY
    • Table 9-3: Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • CELL VS. GENE THERAPY MARKETS
    • Table 9-4: Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
  • REGIONAL MARKET OVERVIEW
    • Table 9-5: Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • UNITED STATES
    • Table 9-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
    • Figure 9-2: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
    • Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA
  • EUROPE/EUROPEAN UNION
    • Table 9-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
    • Figure 9-3: Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
    • Table 9-9: Major Cell and Gene Therapy Approvals by EMA
  • OTHER COUNTRIES
    • Table 9-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
    • Figure 9-4: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
    • Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
  • COMPETITOR RANKING IN CELL AND GENE THERAPY MARKETS
    • Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)

CHAPTER 10: MARKET PARTICIPANTS

  • LEADING INFLUENCERS
  • ADVANTAGENE, INC.
    • Table 10-1: Advantagene Corporate Summary
    • Company Summary
    • Products
  • ADVAXIS, INC.
    • Table 10-2: Advaxis Corporate Summary
    • Company Summary
    • Products
  • ALLOSOURCE
    • Table 10-3: AlloSource Corporate Summary
    • Company Summary
    • Products
  • ALNYLAM PHARMACEUTICALS
    • Table 10-4: Alnylam Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • AMGEN
    • Table 10-5: Amgen Corporate Summary
    • Company Summary
    • Products
  • ANGES INC.
    • Table 10-6: AnGes Corporate Summary
    • Company Summary
    • Products
  • ANTEROGEN CO LTD.
    • Table 10-7: Anterogen Corporate Summary
    • Company Summary
    • Products
  • ATARA BIOTHERAPEUTICS
    • Table 10-8: Atara Biotherapeutics Corporate Summary
    • Company Summary
    • Products
  • ATHERSYS, INC
    • Table 10-9: Athersys Corporate Summary
    • Company Summary
    • Products
  • AVEXIS, INC.
    • Table 10-10: AveXis Corporate Summary
    • Company Summary
    • Products
  • BIOCARDIA
    • Table 10-11: BioCardia Summary
    • Company Summary
    • Products
  • BIOGEN, INC.
    • Table 10-12: Biogen Corporate Summary
    • Company Summary
    • Products
  • BIOMARIN PHARMACEUTICALS
    • Table 10-13: BioMarin Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
    • bluebird bio, Inc
      • Table 10-14: bluebird bio Corporate Summary
    • Company Summary
    • Products
  • BRAINSTORM CELL THERAPEUTICS
    • Table 10-15: Brainstorm Cell Therapeutics Corporate Summary
    • Company Summary
    • Products
  • CALADRIUS BIOSCIENCES
    • Table 10-16: Caladrius Biosciences Corporate Summary
    • Company Summary
    • Products
  • CELYAD
    • Table 10-17: Celyad Corporate Summary
    • Company Summary
    • Products
  • COOK MYOSITE, INC
    • Table 10-18: Cook Myosite Corporate Summary
    • Company Summary
    • Products
  • CYTORI THERAPEUTICS, INC
    • Table 10-19: Cytori Therapeutics Corporate Summary
    • Company Summary
    • Products
  • DENDREON PHARMACEUTICALS LLC
    • Table 10-20: Dendreon Corporate Summary
    • Company Summary
    • Products
  • FERRING PHARMACEUTICALS
    • Table 10-21: Ferring Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • FIBROCELL (CASTLE CREEK BIOSCIENCES)
    • Table 10-22: Fibrocell Corporate Summary
    • Company Summary
    • Products
  • GAMIDA CELL LTD.
    • Table 10-23: Gamida Cell Corporate Summary
    • Company Summary
    • Products
  • GENSIGHT BIOLOGICS S.A.
    • Table 10-24: GenSight Biologics Corporate Summary
    • Company Summary
    • Products
  • GILEAD SCIENCES, INC.
    • Table 10-25: Gilead Sciences Corporate Summary
    • Company Summary
    • Products
  • GRADALIS, INC
    • Table 10-26: Gradalis Corporate Summary
    • Company Summary
    • Products
  • INOVIO PHARMACEUTICALS, INC.
    • Table 10-27: Inovio Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • KIADIS PHARMA B.V.
    • Table 10-28: Kiadis Pharma Corporate Summary
    • Company Summary
    • Products
  • MEDEOR THERAPEUTICS
    • Table 10-29: Medeor Therapeutics Corporate Summary
    • Company Summary
    • Products
  • MEDIPOST CO, LTD.
    • Table 10-30: Medipost Corporate Summary
    • Company Summary
    • Products
  • MERCK & CO., INC.
    • Table 10-31: Merck & Co. Corporate Summary
    • Company Summary
    • Products
  • MESOBLAST LTD.
    • Table 10-32: Mesoblast Corporate Summary
    • Company Summary
    • Products
  • MODERNA, INC
    • Table 10-33: Moderna Corporate Summary
    • Company Summary
    • Products
  • NEUROTECH PHARMACEUTICALS, INC.
    • Table 10-34: Neurotech Corporate Summary
    • Company Summary
    • Products
  • NORTHWEST BIOTHERAPEUTICS, INC.
    • Table 10-35: Northwest Biotherapeutics Corporate Summary
    • Company Summary
    • Products
  • NOVARTIS AG
    • Table 10-36: Novartis Corporate Summary
    • Company Summary
    • Products
  • NUVASIVE BIOLOGICS
    • Table 10-37: NuVasive Biologics Corporate Summary
    • Company Summary
    • Products
  • ORCHARD THERAPEUTICS
    • Table 10-38: Orchard Therapeutics Corporate Summary
    • Company Summary
    • Products
  • ORGANOGENESIS
    • Table 10-39: Organogenesis Corporate Summary
    • Company Summary
    • Products
  • ORTHOFIX MEDICAL INC.
    • Table 10-40: Orthofix Corporate Summary
    • Company Summary
    • Products
  • OSIRIS THERAPEUTICS, INC.
    • Table 10-41: Osiris Corporate Summary
    • Company Summary
    • Products
  • PHARMICELL
    • Table 10-42: Pharmicell Corporate Summary
    • Company Summary
    • Products
  • PLURISTEM THERAPEUTICS, INC.
    • Table 10-43: Pluristem Therapeutics Corporate Summary
    • Company Summary
    • Products
  • QUARK PHARMACEUTICALS
    • Table 10-44: Quark Pharmaceuticals Corporate Summary
    • Company Summary
    • Products
  • REGENERATIVE MEDICAL SYSTEM
    • Table 10-45: Regenerative Medical Corporate Summary
    • Company Summary
    • Products
  • RENOVA THERAPEUTICS
    • Table 10-46: Renova Therapeutics Corporate Summary
    • Company Summary
    • Products
  • SANGAMO THERAPEUTICS
    • Table 10-47: Sangamo Therapeutics Corporate Summary
    • Company Summary
    • Products
  • SANOFI
    • Table 10-48: Sanofi Corporate Summary
    • Company Summary
    • Products
  • SOTIO A.S.
    • Table 10-49: SOTIO Corporate Summary
    • Company Summary
    • Products
  • SPARK THERAPEUTICS
    • Table 10-50: Spark Therapeutics Corporate Summary
    • Company Summary
    • Products
  • TESSA THERAPEUTICS, LTD.
    • Table 10-51: Tessa Therapeutics Corporate Summary
    • Company Summary
    • Products
  • TOCAGEN, INC.
    • Table 10-52: Tocagen Corporate Summary
    • Company Summary
    • Products
  • UNIQURE N.V.
    • Table 10-53: uniQure Corporate Summary
    • Company Summary
    • Products
  • VBL THERAPEUTICS (VASCULAR BIOGENICS LTD.)
    • Table 10-54: VBL Therapeutics Corporate Summary
    • Company Summary
    • Products
  • VERICEL CORPORATION
    • Table 10-55: Vericel Corporate Summary
    • Company Summary
    • Products
  • VIROMED CO LTD (HELIXMITH)
    • Table 10-56: ViroMed Corporate Summary
    • Company Summary
    • Products